Sign in to follow
Search Results

0 results for 'Sanofi SA'

You can use to get even better search results
August 09, 2006 |

Generic Drug Maker Launches Plavix Clone

Shares of Bristol-Myers Squibb sank Tuesday as generic drug maker Apotex disclosed it has begun selling a cheaper version of the pharmaceutical company's drug Plavix. Bristol-Myers and its partner Sanofi-Aventis, which sells Plavix abroad, say their patent has been infringed. The recent focus on generic Plavix began in late July when Bristol-Myers and Sanofi-Aventis announced the Justice Department had launched a criminal probe into an out-of-court settlement they had brokered with Apotex.
3 minute read
October 02, 2009 |

Mergers & Acquisitions

New Jersey mergers and acquisitions.
1 minute read
February 01, 2005 |

A French Affair

Hen we last visited Laurent Cohen-Tanugi, the 47-year-old lawyer was excited to be the new senior vice president for legal affairs and general counsel at the Paris-based pharmaceutical giant Sanofi-Synth�labo [A Renaissance Man, January 2004]. Cohen-Tanugi is now rethinking this attitude-from the vantage point of his new job as a Paris-based partner at Skadden, Arps, Slate, Meagher & Flom. In France, Cohen-Tanugi is considered a rare breed: a lawyer and a public intellectual-the author of six books
3 minute read
May 30, 2006 |

Drug Makers Delay Generics Hitting Market

The marketers of the world's second-largest-selling drug dodged a major threat to their revenues by reaching a deal to keep a generic competitor at bay until at least 2011. Now, 10 lawsuits have been filed over the settlement Sanofi-Aventis SA and Bristol-Myers Squibb reached with Apotex, a generic manufacturer challenging blood thinner Plavix's patent. The suits, filed by businesses, unions and health plans, allege the deal violates antitrust laws by denying access to cheap, generic versions of Plavix.
6 minute read
May 30, 2006 |

Drug Makers Delay Generics Hitting Market

The marketers of the world's second-largest-selling drug dodged a major threat to their revenues by reaching a deal to keep a generic competitor at bay until at least 2011. Now, 10 lawsuits have been filed over the settlement Sanofi-Aventis SA and Bristol-Myers Squibb reached with Apotex, a generic manufacturer challenging blood thinner Plavix's patent. The suits, filed by businesses, unions and health plans, allege the deal violates antitrust laws by denying access to cheap, generic versions of Plavix.
6 minute read
August 30, 2010 |

Stocks dip as investors enter week cautiously

Stocks edged lower today as investors took a cautious approach to trading before the government's latest report on the jobs market.
4 minute read
June 01, 2007 |

Focus Europe: The Arbitration Scorecard

74 minute read
October 09, 2009 |

In re Sanofi-Aventis Securities Litigation

Material Omission, Scienter Not Shown in Fraud Suit Stemming From FDA Denial of Anti-Obesity Drug
1 minute read
January 04, 2012 |

Lower Courts Follow Matrixx's Guidance on Motions to Dismiss

Last March, in the securities class action Matrixx Initiatives v. Siracusano, the U.S. Supreme Court unanimously rejected the defendants' proposed bright-line "statistically significant" rule for determining whether adverse event reports withheld from a pharmaceutical company's public filings are material as a matter of law.
10 minute read
June 21, 2004 |

Arnold & Porter

2 minute read

TRENDING STORIES

    More from ALM

    More from ALM

    Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

    Resources

    • Revenue, Profit, Cash: Managing Law Firms for Success

      Brought to you by Juris Ledger

      Download Now

    • Law Firm Operational Considerations for the Corporate Transparency Act

      Brought to you by Wolters Kluwer

      Download Now

    • The Ultimate Guide to Remote Legal Work

      Brought to you by Filevine

      Download Now

    • Practical Guidance Journal: Protecting Work Product in a Generative AI World

      Brought to you by LexisNexis®

      Download Now